Advertisement

Effective Medications for Treating Psychosis in School-Aged Youth

  • Zachary B. Millman
  • Heidi J. Wehring
  • Alicia R. Khan
  • Sarah Edwards
  • Sharon A. Hoover
  • Jason SchiffmanEmail author
Chapter
Part of the Pediatric School Psychology book series (PSP)

Abstract

Psychotic disorders, including schizophrenia and schizoaffective disorder, are a challenge to both diagnosis and treat in school-age children. The purpose of this chapter is to highlight the efficacy and effectiveness of psychotropic medications used in the treatment of children and adolescents with psychosis. Both the intended and side effects of medication treatments (first-generation antipsychotics, second-generation antipsychotics) commonly used to treat psychotic symptoms are reviewed. A set of references and web-based materials are provided to readers for additional information.

Keywords

Schizophrenia Antipsychotics Atypical antipsychotics Hallucinations Delusions Psychosis 

References

  1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5). Washington, DC: American Psychiatric Pub.CrossRefGoogle Scholar
  2. Addington, J., Addington, D., Abidi, S., Raedler, T., & Remington, G. (2017). CPA treatment guidelines for individuals at clinical high risk of psychosis. The Canadian Journal of Psychiatry, 62(9), 656–661.  https://doi.org/10.1177/0706743717719895.CrossRefPubMedGoogle Scholar
  3. Armando, M., Pontillo, M., & Vicari, S. (2015). Psychosocial interventions for very early and early-onset schizophrenia: A review of treatment efficacy. Current Opinion in Psychiatry, 28(4), 312–323.  https://doi.org/10.1097/YCO.0000000000000165.CrossRefPubMedGoogle Scholar
  4. Bo, S., & Haahr, U. H. (2016). Early-onset psychosis and child and adolescent schizophrenia. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 4(1), 1–3.CrossRefGoogle Scholar
  5. Caccia, S. (2013). Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatric Drugs, 15(3), 217–233.  https://doi.org/10.1007/s40272-013-0024-6.CrossRefPubMedGoogle Scholar
  6. Correll, C. U. (2010). From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. European Psychiatry, 25, S12–S21.  https://doi.org/10.1016/S00924-9338(10)71701-6.CrossRefPubMedGoogle Scholar
  7. Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., … & Carson, W. H. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. American Journal of Psychiatry, 165(11), 1432–1441.  https://doi.org/10.1176/appi.ajp.2008.07061035.CrossRefGoogle Scholar
  8. Findling, R. L., McKenna, K., Earley, W. R., Stankowski, J., & Pathak, S. (2012). Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 22(5), 327–342.  https://doi.org/10.1089/cap.2011.0092.CrossRefPubMedGoogle Scholar
  9. Findling, R. L., Çavuş, I., Pappadopulos, E., Vanderburg, D. G., Schwartz, J. H., Gundapaneni, B. K., et al. (2013). Ziprasidone in adolescents with schizophrenia: Results from a placebo-controlled efficacy and long-term open-extension study. Journal of Child and Adolescent Psychopharmacology, 23(8), 531–544.  https://doi.org/10.1089/cap.2012.0068.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Findling, R. L., Landbloom, R. P., Mackle, M., Pallozzi, W., Braat, S., Hundt, C., … Mathews, M. (2015). Safety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology, 25(5), 384–396.  https://doi.org/10.1089/cap.2015.0027.CrossRefGoogle Scholar
  11. Guloksuz, S., & van Os, J. (2017). The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine, 1–16.  https://doi.org/10.1017/s0033291717001775.CrossRefGoogle Scholar
  12. Haas, M., Eerdekens, M., Kushner, S., Singer, J., Augustyns, I., Quiroz, J., … Kusumakar, V. (2009a). Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. The British Journal of Psychiatry, 194(2), 158–164.  https://doi.org/10.1089/cap.2008.0144.CrossRefGoogle Scholar
  13. Haas, M., Unis, A. S., Armenteros, J., Copenhaver, M. D., Quiroz, J. A., & Kushner, S. F. (2009b). A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology, 19(6), 611–621.  https://doi.org/10.1192/bjp.bp.107.046177.CrossRefPubMedGoogle Scholar
  14. Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., … Ryan, N. (1997). Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36(7), 980–988.  https://doi.org/10.1097/00004583-199707000-00021.CrossRefGoogle Scholar
  15. Kline, E., Denenny, D., Reeves, G., & Schiffman, J. (2014). Early identification of psychosis in schools. In Handbook of school mental health (pp. 323–338). Springer US.  https://doi.org/10.1007/978-1-4614-7624-5_24.Google Scholar
  16. Kryzhanovskaya, L., Schulz, S.C., Mcdougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., … Carlson, J. (2009). Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48(1), 60–70.  https://doi.org/10.1097/chi.0b013e3181900404.CrossRefGoogle Scholar
  17. Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H.M., DeThomas, C., Kafantaris, V., … Kane, J.M. (2008). Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry, 63(5), 524–529.  https://doi.org/10.1016/j.biopsych.2007.04.043.CrossRefGoogle Scholar
  18. Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O., … Altshuler, K. (2004). Practice guideline for the treatment of partients with schizophrenia. American Journal of Psychiatry, 161(2 SUPPL).Google Scholar
  19. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., et al. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063–2071.  https://doi.org/10.1016/S0140-6736(12)60239-6.CrossRefGoogle Scholar
  20. Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., … Taylor, D. (2016). Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? The British Journal of Psychiatry, 209(5), 361–365.  https://doi.org/10.1192/bjp.bp.116.182683.CrossRefGoogle Scholar
  21. Nesvag, R., Hartz, I., Bramness, J. G., Hjellvik, V., Handal, M., & Skurtveit, S. (2016). Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. European Neuropsychopharmacology, 26(9), 1412–1418.  https://doi.org/10.1016/j.euroneuro.2016.07.001.CrossRefPubMedGoogle Scholar
  22. Olfson, M., King, M., & Schoenbaum, M. (2015). Treatment of young people with antipsychotic medications in the United States. Journal of the American Medical Association, Psychiatry, 72(9), 867–874.  https://doi.org/10.1001/jamapsychiatry.2015.0500.CrossRefGoogle Scholar
  23. Pagsberg, A. K., Tarp, S., Glintborg, D., Stenstrom, A. D., Fink-Jensen, A., Correll, C. U., et al. (2017). Acute antipsychotic treatment of children and adolescents with schizophrenia—Sperctrum disorders: A systematic review and network meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 56(30), 191–202.  https://doi.org/10.1016/j.jaac.2016.12.013.CrossRefPubMedGoogle Scholar
  24. Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K., Isometsä, E., Pirkola, S., … Kieseppä, T. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry, 64(1), 19–28.  https://doi.org/10.1001/archpsyc.64.1.19.CrossRefGoogle Scholar
  25. Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. American Journal of Psychiatry, 162(10), 1785–1804.  https://doi.org/10.1176/appi.ajp.162.10.1785.CrossRefPubMedGoogle Scholar
  26. Savitz, A. J., Lane, R., Nuamah, I., Gopal, S., & Hough, D. (2015). Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. Journal of the American Academy of Child and Adolescent Psychiatry, 54(2), 126–137. e121.  https://doi.org/10.1016/j.jaac.2014.11.009.CrossRefGoogle Scholar
  27. Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., … Bhattacharyya, S. (2016). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. The Lancet Psychiatry, 3(3), 215–225.  https://doi.org/10.1016/S2215-0366(15)00363-6.CrossRefGoogle Scholar
  28. Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., … Rapoport, J. L. (2006). Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry, 63(7), 721–730.  https://doi.org/10.1001/archpsyc.63.7.721.CrossRefGoogle Scholar
  29. Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L. …Michael, E. (2008). Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry, 165(11), 1420–1431.  https://doi.org/10.1176/appi.ajp.2008.08050756.CrossRefGoogle Scholar
  30. Singh, J., Robb, A., Vijapurkar, U., Nuamah, I., & Hough, D. (2011). A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biological Psychiatry, 70(12), 1179–1187.  https://doi.org/10.1016/j.biopsych.2011.06.021.CrossRefPubMedGoogle Scholar
  31. Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016). Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis. The British Journal of Psychiatry, 209(5), 385–392.  https://doi.org/10.1192/bjp.bp.115.17726.
  32. Tempelaar, W. M., Termorshuizen, F., MacCabe, J. H., Boks, M. P., & Kahn, R. S. (2017). Educational achievement in psychiatric patients and their siblings: A register-based study in 30 000 individuals in The Netherlands. Psychological Medicine, 47(4), 776–784.  https://doi.org/10.1017/S0033291716002877.CrossRefPubMedGoogle Scholar
  33. Thompson, E., Millman, Z. B., Okuzawa, N., Mittal, V., DeVylder, J., Skadberg, T., … Schiffman, J. (2015). Evidence-based early interventions for individuals at clinical high risk for psychosis: A review of treatment components. The Journal of Nervous and Mental Disease, 203(5), 342–351.  https://doi.org/10.1097/nmd.00000000000000287.
  34. Tsuji, T., Kline, E., Sorensen, H. J., Mortensen, E. L., Michelsen, N. M., Ekstrom, M., … Schiffman, J. (2013). Premorbid teacher-rated social functioning predicts adult schizophrenia-spectrum disorder: a high-risk prospective investigation. Schizophrenia Research, 151(1), 270–273.  https://doi.org/10.1016/j.schres.2013.10.022.CrossRefGoogle Scholar
  35. Vallarino, M., Henry, C., Etain, B., Gehue, L. J., Macneil, C., Scott, E. M., … Scott, J. (2015). An evidence map of psychosocial interventions for the earliest stages of bipolar disorder. The Lancet Psychiatry, 2(6), 548–563.  https://doi.org/10.1016/s2215-0366(15)00156-x.CrossRefGoogle Scholar
  36. Watson, A. C., Otey, E., Westbrook, A. L., Gardner, A. L., Lamb, T. A., Corrigan, P. W., et al. (2004). Changing middle schoolers’ attitudes about mental illness through education. Schizophrenia Bulletin, 30(3), 563–572.  https://doi.org/10.1093/oxfordjournals.schbul.a007100.CrossRefPubMedGoogle Scholar
  37. Young, S. L., Taylor, M., & Lawrie, S. M. (2015). First do no harm. A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of Psychopharmacology, 29(4), 353–362.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Zachary B. Millman
    • 1
  • Heidi J. Wehring
    • 2
  • Alicia R. Khan
    • 1
  • Sarah Edwards
    • 2
  • Sharon A. Hoover
    • 2
  • Jason Schiffman
    • 1
    Email author
  1. 1.University of Maryland, Baltimore CountyBaltimoreUSA
  2. 2.School of MedicineUniversity of MarylandBaltimoreUSA

Personalised recommendations